CompletedPHASE1, PHASE2NCT02406651

Study of IL-22 IgG2-Fc (F-652) for Subjects With Grade II-IV Lower GI aGVHD

Studying Graft versus host disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
EVIVE Biotechnology
Principal Investigator
Doris Ponce, M.D.
MSKCC
Intervention
Recombinant Human Interleukin-22 IgG2-Fc (F-652)(drug)
Enrollment
30 target
Eligibility
18-80 years · All sexes
Timeline
20162020

Study locations (3)

Collaborators

Memorial Sloan Kettering Cancer Center

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02406651 on ClinicalTrials.gov

Other trials for Graft versus host disease

Additional recruiting or active studies for the same condition.

See all trials for Graft versus host disease

← Back to all trials